SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Lantern Pharma appoints David Margrave interim CEO

The appointment is effective Nov. 16, 2026, according to an SEC filing.

LTRN

Related stories